The prevalence of samples with HLA-A loss in primary tumors ranged between 0% (cervical cancer, esophageal cancer) and 41% (breast cancer) and between 0% (esophageal cancer and melanoma) and 50% loss (breast cancer) in metastatic disease. This evidence concerns the gene HLA-A and breast cancer.